Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

CSP Introduces Activ-Blister® Technology for Pharmaceutical Manufacturers

Published: Monday, October 22, 2012
Last Updated: Monday, October 22, 2012
Bookmark and Share
Innovative desiccated blister packaging protects moisture and oxygen-sensitive solid dose pharmaceuticals for better product performance.

CSP Technologies has announced the global launch of its Activ-Blister® desiccated blister packaging for the pharmaceutical industry.

Activ-Blister® desiccant film technology controls the internal atmosphere of each individual blister cavity, protecting moisture and oxygen-sensitive solid dose pharmaceuticals.

The result is optimized product stability, increased shelf-life, and greater consumer convenience.

Activ-Blister® also helps ensure consumer safety, because unlike conventional desiccants, there is no chance of accidental ingestion.

Activ-Blister® offers manufacturers superior flexibility in packaging design, providing an opportunity to differentiate their products.

By eliminating the need for traditional desiccant tablets in separate blister wells, Activ-Blister® allows for a slimmer, more convenient packaging form-factor while simplifying the end-user experience.

In addition, by featuring product protection without increased blister size, Activ-Blister® provides manufacturers with potential cost savings through reduced material usage, freight costs and fuel consumption.

“Activ-Blister® is an entirely new approach to protecting pharmaceuticals with specialized packaging that can build a unique identity for brands,” according to Dan L’Ecuyer, Vice President of Sales & Marketing at CSP Technologies.

L’Ecuyer continued, “Rather than use a desiccant chip inside a separate well in a blister, our proven technologies provides all the protection without increasing blister size and material or shipping costs.”

CSP’s patented technology integrates precise desiccant, gas-absorption, and sealing properties into the blister-pack itself, extending shelf life and product performance.

Activ-Blister® exhibits excellent performance capacity with moisture absorption up to 20mgs and oxygen scavenging up to 30ccs.

In addition, CSP’s Activ-Blister®® technology is available in a variety of sizes, including all type of round tablets and capsules up to size 0, with either multilayer barrier films or aluminum foil blisters to provide protection from both moisture and oxygen.

“Safely preserving drug potency and extending shelf life are high priorities for pharmaceutical manufacturers, and for the patients who rely on their products,” says L’Ecuyer.

“Activ-Blister®, CSP’s breakthrough solid dose packaging technology provides a strong product solution that meets customer needs while also safeguarding patient health.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos